头颈部放疗后颈动脉狭窄患者与动脉粥样硬化性狭窄患者颈动脉支架置入术的结局比较
本研究基于2016至2019年美国血管质量倡议(Vascular Quality Initiative)颈动脉支架置入术(CAS)数据集(n=7343),比较头颈部放疗(RT)后与动脉粥样硬化性狭窄患者接受CAS的围术期结局、再狭窄、再干预及死亡风险。结果显示RT组3年死亡率9.4% vs 无RT组7.5%(P=0.03),校正后死亡风险增加58%(校正HR 1.58,95%CI 1.13-2.21),但围术期并发症、再狭窄及再干预无显著差异。
要点
- RT组3年死亡率9.4% vs 无RT组7.5%(P=0.03),校正后死亡风险增加58%(校正HR 1.58,95%CI 1.13-2.21)。
- RT组与无RT组围术期心肌梗死、院内死亡、同侧或对侧卒中、再狭窄(>50%或>70%)及再干预风险无显著差异。
- 作者认为,对于这一高危人群,CAS提供的通畅率与动脉粥样硬化性颈动脉狭窄相同,并避免潜在的颅神经损伤和伤口愈合并发症。
核心结论
- RT组CAS患者在随访各时间点的死亡率均显著高于无RT组,校正其他协变量后仍显著。
- 两组围术期并发症、再干预及再狭窄发生率无显著差异。
- 作者认为,对于这一高危人群,CAS提供的通畅率与动脉粥样硬化性颈动脉狭窄相同,并避免潜在的颅神经损伤和伤口愈合并发症。
研究设计与样本
- 基于美国血管质量倡议(Vascular Quality Initiative)CAS数据集2016至2019年的样本进行分析(n=7343)。
- 主要自变量为既往头颈部和/或颈部放疗;主要终点为至死亡的时间间隔。
- 次要终点为再狭窄(双功超声>50%和>70%)及再干预的累积发生率,以及围术期心肌梗死、院内死亡、神经系统事件、同侧卒中和对侧卒中。
- 采用Kaplan-Meier和多变量Cox比例风险模型评估死亡率,采用累积发生率函数估计非致死性终点。
主要发现
- 在7218例患者中,1199例(17%)有既往RT史。
- RT组与无RT组3年死亡率估计值分别为9.4%和7.5%(P=0.03)。
- 校正分析显示,既往RT组死亡风险增加58%(校正HR 1.58,95%CI 1.13-2.21)。
- 既往RT组与无RT组在围术期并发症(心肌梗死、院内死亡、同侧或对侧卒中)、再狭窄(>50%或>70%)或再干预风险方面无差异。
临床怎么用
- 作者认为,对于这一高危人群,CAS提供的通畅率与动脉粥样硬化性颈动脉狭窄相同,并避免潜在的颅神经损伤和伤口愈合并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Head and neck malignancies are often treated with radiotherapy (RT). Nearly 80% of patients who have undergone RT will develop carotid radiation arteritis to some degree and 29% will develop stenosis >50%. Surgery in a radiated neck has higher rates of complications, and carotid artery stenting (CAS) has become the primary therapy. The outcomes for CAS in patients with radiation arteritis have not been rigorously evaluated. The objective of the present study was to evaluate the differences in perioperative outcomes, restenosis rates, the need for reintervention, and freedom from mortality between RT patients and patients with atherosclerotic disease who had undergone CAS. METHODS: The national Vascular Quality Initiative CAS dataset from 2016 to 2019 comprised the sample for analyses (n = 7343). The primary independent variable was previous head and/or neck RT. The primary endpoint was the interval to mortality. The secondary endpoints were the cumulative incidence of restenosis (>50% and >70% by duplex ultrasound) and reintervention. We also examined the following secondary perioperative endpoints: myocardial infarction, in-hospital mortality (death before discharge), neurologic events, ipsilateral stroke, and contralateral stroke. Kaplan-Meier and multivariable Cox proportional hazard models were used to assess for mortality, and cumulative incidence function estimates were used for the nonfatal endpoints. RESULTS: Of the 7218 patients, 1199 (17%) had undergone prior RT. We found a significant difference in the 3-year estimates of mortality for those with and without prior RT (9.4% and 7.5%, respectively; P = .03). Furthermore, on adjusted analysis, we observed a 58% increase in the risk of mortality for those with prior RT (adjusted hazard ratio, 1.58; 95% confidence interval, 1.13-2.21). We did not observe any differences in the risk of perioperative complications (myocardial infarction, in-hospital mortality, ipsilateral or contralateral stroke), restenosis (>50% or >70%), or reintervention for the prior RT group compared with those without RT. CONCLUSIONS: The CAS patients with RT had significantly greater mortality at all time points compared with those without RT, even after adjusting for other covariates. No significant difference was found in the incidence of perioperative complications, reintervention, or restenosis between the two groups. The present study is unique because of the large sample size and length of follow-up. The results suggest that for this high-risk group, CAS provides the same patency as it does for atherosclerotic carotid stenosis and avoids potentially morbid cranial nerve injury and wound healing complications.
引用
- Minc SD, Thibault D, Marone L, et al. Outcomes of carotid artery stenting in patients with radiation arteritis compared with those with atherosclerotic disease. J Vasc Surg. 2021. PMID: 34861360. doi:10.1016/j.jvs.2021.11.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。